Sylvie Binda, vice-president research and development at Lallemand Health Solutions has been elected as a new member of the board of directors of Pharmabiotic Research Institute (PRI), as announced during the annual general assembly and member event, in Rotterdam, the Netherlands.
Lallemand Health Solutions is one of the founding members of the PRI, a non-profit organization created in 2010, aiming at clarifying the specific scientific and regulatory requirements of Microbiotic Medicinal Products in Europe. Over the years, the PRI has gathered an unmatched expertise around the development and registration of therapeutic and diagnostic products emerging from microbiome science. This expertise is shared with the members in a collaborative approach. In addition, the PRI is recognized as the expert of microbiome regulatory science by stakeholders and involved in discussions on the development of new standards in this field.
“It’s an honor for me and a great mark of trust to have been elected by the Pharmabiotic Research Institute members to sit on the board of directors and I will do my utmost to uphold and contribute to the mission and the vision of the organization,” confirms Mrs. Binda.
PRI counts more than 100 member organizations, representing various expertise and interests in the microbiome development field, from early-stage academic researchers all the way to contract manufacturers and commercialization.
Lallemand Health Solutions produces probiotics for the dietary supplements, pharmaceutical, food, and nutricosmetic industries. With its manufacturing processes adhering to the highest quality standards and its ambitious research program, Lallemand Health Solutions provides probiotic strains that help millions of people improve their health and well-being.
Marilou Luneau, Content Manager
Lallemand Health Solutions